Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1196 participants.

Also called NCT07763405

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,196 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07763405
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07763405. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic Stroke
Condition
Ischemic Stroke, Acute
Intervention (Drug)
Lumbrokinase
Intervention (Drug)
Lumbrokinase Placebo
Lead sponsor
Xinqiao Hospital of Chongqing (class: other)
Collaborator
The First Affiliated Hospital of Nanchang University (class: other)

Record details

Record id
cardio:ct-nct07763405
Content hash
dc67123519a0ade8c41c66a1d9bdd26707a13fd54fe594c7ffbd09fc1ec168a8